Latest / Stock Movers / AG Barr Drops, LandSec Falls, Sanofi Gains
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio, news. The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg data.
- 0:15Speaker 2: Let's take a look now at some stocks on the
- 0:18Speaker 2: move today in Europe. I'm Nathan Hager with Caroline Hepker,
- 0:21Speaker 2: joined by Bloomberg's Louise Moon, keeping an eye on AG Bar,
- 0:26Speaker 2: the stock is falling this morning. Not so fizzy for
- 0:30Speaker 2: AG Bar investors, is it, Louise?
- 0:31Speaker 3: Indeed, no. Shares down as much as about 4.7% this morning. So,
- 0:35Speaker 3: that's their lowest level since April 2024. This is on
- 0:39Speaker 3: the back of a downgrade by Berenberg. So, they've been
- 0:41Speaker 3: downgraded from a buy to a hold. And Berenberg's also
- 0:45Speaker 3: cut the price target as well. They are noting a
- 0:48Speaker 3: or they're expecting, they're seeing subdued volume growth. So, AG Bar, obviously,
- 0:53Speaker 3: the maker of a lot of soft drinks, for example,
- 0:56Speaker 3: Iron Brew, a popular drink in Scotland, in particular. But
- 1:00Speaker 3: Berenberger noting that like-for-like sales were broadly flat in the
- 1:03Speaker 3: first half. Supply and chain disruptions in the second quarter.
- 1:09Speaker 3: And yeah, the overall performance is subdued, given what it
- 1:12Speaker 3: thinks is a good trading environment. Obviously, there's quite a
- 1:15Speaker 3: shift there. partly quite a shift away from alcohol or towards, uh,
- 1:20Speaker 3: soft drinks. So potentially could boost AG bar, but they're
- 1:23Speaker 3: not seeing that.
- 1:25Speaker 1: Okay. Can I admit to something terrible? I've actually never
- 1:28Speaker 1: drunk an iron brew.
- 1:29Speaker 2: Can I admit to something amazing? I actually have drunk
- 1:33Speaker 2: iron brew.
- 1:34Speaker 1: Yes.
- 1:34Speaker 2: I've been, I've been to Scotland, uh, many, many moons ago. And, um, Yeah,
- 1:39Speaker 2: it's a little bit like for our U.S. listeners, Mountain Dew,
- 1:41Speaker 2: a little bit, except the color is completely different. It's
- 1:44Speaker 2: orange instead of green. Well, yeah, they're both very bright drinks,
- 1:48Speaker 2: but yeah, it's a good mixer if it's that time
- 1:51Speaker 2: of day.
- 1:52Speaker 1: I have to go beyond that.
- 1:53Speaker 3: I was comparing it also to cream soda. Okay, all right. Yeah. Okay.
- 1:59Speaker 1: Very good.
- 2:00Speaker 3: That diversion aside, what about Lansac? How are investors reacting
- 2:05Speaker 3: to Lansac in the UK? So, shares have dipped slightly,
- 2:09Speaker 3: but they're pretty flat through the year in general. So,
- 2:11Speaker 3: the news this morning is that they're planning to raise
- 2:13Speaker 3: £ 500 million through a share sale. That's partly going to
- 2:16Speaker 3: be used– well, they're going to use that to fund
- 2:19Speaker 3: buying a shopping centre called Metro Centre, which is near Newcastle.
- 2:24Speaker 3: It's one of Britain's largest shopping centres. They're buying that
- 2:27Speaker 3: for $ 516 million. So, that share sale will fund some
- 2:32Speaker 3: of that acquisition. And then the rest they're going to
- 2:35Speaker 3: meet by using existing borrowings. So, as I say, shares
- 2:40Speaker 3: dipped slightly on this. LandSec in general has been reducing
- 2:46Speaker 3: exposure to offices, so lower yielding offices and buying up
- 2:50Speaker 3: retail properties. This is part of that push. The CEO
- 2:54Speaker 3: has in particular saying that a major retail destination is
- 2:58Speaker 3: the highest conviction call, but potentially not convincing markets totally
- 3:02Speaker 3: this morning. As I say, that acquisition price of £ 516 million,
- 3:06Speaker 3: that would only represent about half of what it would
- 3:08Speaker 3: cost to rebuild Metro Centre. So, potentially partly on those
- 3:12Speaker 3: big costs that are coming down the line.
- 3:14Speaker 1: Yeah, they're a massive landlord, aren't they, across the UK? Yeah. Okay.
- 3:17Speaker 2: So, moving on from real estate to big pharma, we've
- 3:20Speaker 2: got some news from Sanofi, some expanding news.
- 3:24Speaker 3: Tell us more. Indeed, yes. They've expanded their partnership with
- 3:26Speaker 3: a U.S.-listed firm, Regeneron Pharmaceuticals. This is to co-develop and
- 3:32Speaker 3: co-commercialize four new drugs. So, these are antibody drugs for
- 3:35Speaker 3: diseases related to the immune system. The two companies have
- 3:38Speaker 3: collaborated before. So, this is the latest collaboration. collaboration for them.
- 3:44Speaker 3: Analysts are saying that for Sanofi, it's a significant win.
- 3:48Speaker 3: The deal has quite good terms. It's the first step
- 3:51Speaker 3: in addressing their long-term outlook and a clear sign of progress. Essentially,
- 3:55Speaker 3: they've been under quite a lot of that they had
- 4:02Speaker 3: previously collaborated on, the two companies, when that patent begins
- 4:05Speaker 3: to expire in early 2030s, they then need to replace
- 4:09Speaker 3: that income. So, this is a first step in addressing that.
- 4:12Speaker 3: And shares rising on the back of that, they're up
- 4:14Speaker 3: about 3.7% in Paris.
- 4:17Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:21Speaker 1: us throughout the day for the latest roundup of companies
- 4:24Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 4:28Speaker 1: listen to Bloomberg Radio live. Catch us on YouTube, Bloomberg.com,
- 4:33Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:36Speaker 1: Business app.